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Scientists from Oxford have taken
another step along the frustrating
route to an effective malaria vaccine.
This autumn, Vasee Moorthy of
Oxford University’s Department of
Clinical Medicine, working with
scientists at the Medical Research
Council’s Laboratories in the Gambia,
began trials of new DNA-based
vaccines against the malaria parasite
Plasmodium falciparum. The vaccines,
developed by Adrian Hill and
colleagues in the same department,
have been in phase I trials of safety
and immunogenicity in healthy
volunteers in Britain since August
1999. But this is the first time
vaccines of this type have been tested
in Africa, where malaria kills a million
people, mostly children, every year.
The first trials in the Gambia,
like the Oxford trial, are funded by
the Wellcome Trust and will look at
the safety of the new vaccines and
the size of the immune response
they evoke in healthy adult men.
“Most people who grow up in an
endemic area develop substantial
natural immunity,” says Hill, “but it
takes too long to protect young
children. If we could convert the
immune system of a one-year-old
into the immune system of a ten-
year-old, we could very substantially
reduce malaria mortality.”
Parasitic diseases present
particular problems for vaccine
development. Plasmodium falciparum
is a complex organism with a multi-
stage life cycle spent partly in the
guts and salivary glands of
mosquitoes and partly in the liver
and blood of human beings. At each
stage of its life cycle it expresses
different proteins, allowing it to play
‘now you see me, now you don’t’
with the human immune system.
Since the 1980s vaccines have been
developed in laboratories all over the
world, based on 30 or more likely-
looking proteins, but so far none has
evoked a strong enough immune
response to form the basis of a
malaria prevention programme.
Even if it is only partially effective,
it could save many lives
The Oxford vaccine differs from
previous candidates in a number of
ways. First, Hill and his colleagues
realised that they needed to target
the most effective component of the
immune response. In malaria, that
turned out to be not the antibody
response, the target of vaccines
against many other diseases, but the
cell-mediated response. While
antibodies neutralise foreign
antigens by binding to them,
cytotoxic T cells, or killer cells, are
also produced during infections to
seek and destroy infected cells. To
stimulate the cell-mediated
response, Hill decided to use a DNA
vaccine rather than the more
conventional protein or peptide
products. Injected DNA — the exact
sequence chosen to correspond to an
antigen that looks like a promising
candidate — enters the cells of the
host and makes the proteins that will
trigger the immune response.
Finally, the team used a novel
belt-and-braces approach called
heterologous prime-boost
immunisation. This involves
injecting the same antigen in two
different forms of vaccine one after
another — an approach Hill
originally tried in some desperation
when none of the individual vaccines
under test in his lab worked well
enough on its own. The result was
spectacular, providing mice with a
high level of protection against the
malaria parasite. “That looked so
attractive a few years ago, not only in
malaria but in other areas such as
HIV, that we thought it was
important to see if it worked in
people as well,” says Hill.
The two vaccines both contain
the complete gene sequence that
codes for a parasite surface protein
called TRAP (thrombospondin-
related adhesion protein, or
anonymous protein), one of the
family of proteins that enables the
parasite to stick to human cells
before invading them. It is expressed
both during the sporozoite stage of
the parasite’s life cycle, the form that
infected mosquitoes inject into
humans with each bite, and early in
the subsequent liver stage. The
vaccine also contains several
fragments of five other antigens
expressed by liver-stage parasites.
Hill’s team identified these short
peptide epitopes as the targets of
cytotoxic T cells found in the blood
of Africans immune to malaria.
When the parasites first arrive in
the liver and enter its cells they are
relatively few in number, and the
victim has yet to show symptoms of
illness. Once they have taken up
residence in the cells, they divide
rapidly before bursting out into the
bloodstream in huge numbers. Hill’s
goal is to produce a vaccine that will
stimulate cytotoxic T cells to destroy
all the infected cells in the liver
before the parasite has a chance to
multiply.
As well as the DNA vaccine,
injected into the muscle, the second
component of the ‘prime-boost’
strategy is a recombinant viral
vaccine called modified vaccinia
virus Ankara (MVA), engineered to
include DNA sequences for the
malaria epitopes and TRAP, and
injected into the skin. This non-
replicating virus, which has never
been used in recombinant form
before, was safely used two decades
ago in a smallpox immunisation
programme. The trials in the UK
over the past year have tested each
vaccine separately. Both proved safe,
and both evoked an immune
response. Trials of the two vaccines
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in combination are still under way.
“We were sufficiently encouraged to
go ahead in the Gambia,” says Hill.
“It will be interesting to compare the
strength of the response in people
who have never been infected and in
people whose immune systems have
seen the parasite before.” By the end
of the year, Moorthy hopes to have
tested each vaccine separately as
well as the two in combination in a
small group of volunteers.
The next step will be to test the
efficacy of the vaccine against the
parasite itself. “If all goes well, we
plan to vaccinate another group of
volunteers in the UK and challenge
them with malaria sporozoites, using a
drug-sensitive strain of malaria,” says
Hill. While this approach may sound
risky, it has already been successfully
used with a very different candidate
vaccine known as RTS,S, developed
by SmithKline Beecham Biologicals
together with the Walter Reed Army
Institute of Research in the US and
others. The RTS,S vaccine is a
protein-based vaccine used with a
novel immunostimulatory adjuvant,
and has now moved on to field trials,
also in the Gambia. RTS,S protected
the majority of vaccinated volunteers,
but this protection appears to last for
months rather than years. The
vaccine’s developers now plan to test
prime-boost strategies with RTS,S to
see if that can improve its
performance.
Before they embark on large-
scale vaccination programmes, those
in charge of public health in
countries where malaria is endemic
will want to see evidence that
vaccines protect a substantial
proportion of the vulnerable
population, that they are long-lasting,
and that they do not themselves
cause illness. But even if the DNA
vaccine “is only partially effective, it
could save many lives,” says Hill.
“And it should be easier to boost
immunity that is already present
than to try to create it from scratch.”
Georgina Ferry is a freelance science writer
based in Oxford, UK.
Cheats and poachers beware.
Multi-locus genotype analyses,
which have been widely used to
assign individuals to the particular
populations they are most likely to
have originated from, have come
to the aid of suspicious fishing
competition judges in Finland.
When presented with an unusually
large salmon the judges were
concerned that the 5.5 kg
specimen may have come from
the local fishmonger and not the
competition lake. So they
contacted biologist Craig Primmer
and his team at the department of
ecology and systematics at the
University of Helsinki. Salmon in
the competition lake — Lake
Saimaa — spend their whole life
in freshwater and are maintained
artificially by hatchery stock since
hydroelectric power plants
destroyed their spawning grounds
in the 1950s, and only rarely reach
this size. 
The team began by collecting
tissue samples from the suspect
fish, Lake Saimaa salmon and
individuals from three other
Nordic populations. 
The team chose microsatellite
region analysis because of the
highly polymorphic loci in many
species. Seven loci were chosen
and three analyses were carried
out. The results revealed that the
Saimaa salmon were quite
distinctive from the other
populations with much lower
genetic diversity at these loci.
But the suspect fish failed to show
these distinctive characteristics and
after all the analyses the team
informed the competition judges
that they estimated the salmon was
600 times more likely to come from
a fishery outside Lake Saimaa. 
When confronted with this
evidence the fisherman confessed
that he had bought the salmon at a
local fish shop and criminal charges
were laid. Primmer believes these
techniques may be helpful in other
disputes about the origin of
individual animals, such as
poaching.
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Fish or foul?
Local fish: genotype analysis has helped
identify a rogue salmon presented to
judges in a Finnish fishing competition on
Lake Saimaa. (Photo: Jorma Piironen).
